A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms

Healthy Volunteers Clinical Trial

Official title:

A SingleDose Rand, TwoPeriod, Crossover Bioequivalence Study Between a Combination Tablet With Paracetamol, Guaifenesin and Penylephrine HCL (Wrafton Lab Ltd, UK) and Vicks Active SymptoMax Plus, Powder for Oral Solution (Wrafton Lab Ltd, UK) in Healthy Adult Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03213353
• Other study ID #: CO-160408130708-URCT
• Status: Completed
• Phase: Phase 1
• Start date: July 3, 2017
• Est. completion date: July 17, 2017

Study information

• Verified date: July 2018
• Source: Johnson & Johnson Consumer and Personal Products Worldwide
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-dose, randomized, two-period cross-over study with 72 healthy male and female volunteers. The investigational products will be given (after fasting overnight) at separate visits separated by 7 ± 3 days. Blood for pharmacokinetic analyses will be drawn pre-dose and at 5, 10, 15, 20, 25, 30, 40, 60, 75, 90, 105 minutes, as well as 2, 2.25, 3, 4, 5, 6, 8, and 12 hours after drug administration. Subjects will also be monitored to capture any adverse events that may occur. Bioequivalence will be assessed based on the single-dose pharmacokinetics of paracetamol, guaifenesin and phenylephrine, respectively

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: July 17, 2017
• Est. primary completion date: July 17, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Subjects being verified as "Healthy": "Healthy" is defined as absence of any diseases or abnormalities on the basis of physical examination, standard clinical laboratory, and instrumental examinations performed at the screening visit.

2. Females of childbearing potential must have a negative urine pregnancy test at the baseline visit.

3. Male or non-pregnant, non-lactating female agree to the contraceptive requirements (including female partner's use of a highly effective method of birth control for at least 3 months before the study, during the study, and for 30 days after the last dose of study drug) as outlined in Section 11.6 (Note: Female subjects are not permitted to use hormonal contraceptives as per exclusion criterion 7).

4. Body Mass Index (BMI) between 18.5 and 30.0 kg/m2, inclusive, and a total body weight of at least 50.0 kg.

5. Volunteers who agree to abstain from alcohol consumption for at least 48 hours prior to dosing and until the last blood sample collection of each study period.

Exclusion Criteria:

1. Use of medications, including prescription medication, over-the-counter medication including vitamins, herbal supplements, medicinal plants (e.g., supplements containing garlic extract), and topical preparations of drugs that are systemically absorbed (e.g., steroids and non-steroid anti-inflammatory drugs) within two weeks prior to dosing.

2. Use of St. John's wort (Hypericum perforatum) within 30 days prior to dosing.

3. Depot injection or an implant of any drug within 3 months prior to dosing.

4. Abnormal results of laboratory and instrumental methods of examinations, including electrocardiogram (ECG).

5. Is hypersensitive, intolerant, or has experienced an allergic reaction to the active ingredients or excipients of drug products that will be used for the study, or has had severe allergy (e.g., anaphylaxis, angioedema) in the past.

6. Females with a positive pregnancy test and/or are breast-feeding.

7. Females, currently using hormonal contraceptives (including use less than 2 months prior to enrollment).

8. Males with a pregnant spouse or partner or males who are not willing to prevent conception in a spouse or partner.

9. History of regular alcohol consumption in the 6 months before screening, exceeding weekly limits of 10 alcohol units (2 L of wine or 5 L of beer or 0.5 L of spirits) or presence of information on alcoholism, substance, or drug abuse in medical history.

10. Alcohol consumption within 48 hours prior to dosing, positive respiratory alcohol test at screening, or inability to abstain from alcohol consumption until the last blood sample collection of each study period.

11. Volunteers who smoke more than 10 cigarettes per day or have an uncontrollable habit of chewing or inhaling nicotine products.

12. Drug addiction in history, or a positive urine test for psychoactive or narcotic substances.

13. Use of caffeine products exceeding 500 mg caffeine daily (5 cups of coffee) and the inability to abstain from caffeine products within 48 hours before dosing and prior to the last blood sample collection of each study period.

14. Use of xanthine containing products (e.g., coffee, tea, chocolate, or cola drink) within 48 hours before dosing and prior to the last blood sample collection of each study period.

15. Ingestion of food or beverages containing grapefruit, Chinese grapefruit (pomelo), or Seville oranges (including marmalade) within 10 days prior to the first dose of the investigational product and inability to stop taking these products during the study.

16. Positive test for human immunodeficiency virus (HIV) 1 or 2 antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (anti-HCV) or syphilis (RW).

17. Heart rate <60 or >90 per minute at rest, or systolic blood pressure <100 or >130 mm Hg, or diastolic blood pressure <70 or >90 mm Hg.

18. Clinically significant signs and symptoms or history of respiratory, cardiovascular, gastrointestinal, dermatological, neurological, psychiatric, genitourinary, endocrinological, musculoskeletal, eye, ear, nose and throat disease, liver disorders, severe chronic kidney disease, active gastric or duodenal ulcer, benign prostate hyperplasia, phenylketonuria, hypertension, hyperthyroidism, diabetes, heart disease, aortic stenosis, tachyarrhythmia, glaucoma or phaeochromocytoma.

19. Hereditary problems of glucose-galactose malabsorption, fructose intolerance, or sucrose/isomaltase deficiency.

20. History of gastrointestinal surgery other than appendectomy.

21. Medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.

Related Conditions & MeSH terms

• Bioequivalence
• Healthy Volunteers

Intervention

Drug:
• Tablet paracetamol, guaifenesin and phenylephrine HCL
Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
• Vicks Active SymptoMax Plus powder for oral solution
Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride

Locations

Country	Name	City	State
Russian Federation	Scientific Research center Eco-Safety LLC	Saint Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Consumer and Personal Products Worldwide

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Plasma Concentration (Cmax) of paracetamol, guaifenesin and phenylephrine (total)	The maximum observed plasma concentration (Cmax)	At baseline and during 12 hours after product administration
Primary	The area under the plasma concentration-vs.-time curves from start of drug administration until the time of the last measurable concentration (AUCt) for paracetamol, guaifenesin and phenylephrine (total)	AUCt is defined as area under the plasma concentration versus time curves from start of drug administration until the last measureable concentration.	At baseline and during 12 hours after product administration
Primary	The area under the concentration-vs.-time curve extrapolated to infinity (AUC8) for paracetamol, guaifenesin and phenylephrine (total)	AUC8 is defined as area under the plasma concentration versus time curves from start of drug administration until the plasma concentration is negligible (infinity).	At baseline and during 12 hours after product administration
Primary	The extrapolated part of AUC8, AUCExtrap of paracetamol, guaifenesin and phenylephrine (total)	AUCextrap is defined as area under the plasma concentration versus time curves from 12 hours until infinity	From 12 hours after start of drug administration until up to 96 hours
Primary	The time at which the maximum plasma concentration is observed (tmax) for paracetamol, guaifenesin and phenylephrine (total)	Tmax is defined as the time point at which the maximum plasma concentration (Cmax) occurs	At baseline and during 12 hours after product administration
Primary	The half-life (t1/2) for paracetamol, guaifenesin and phenylephrine (total) in plasma	The half-life i defined as the time taken for the plasma concentration to fall to half its original value	At baseline and during 12 hours after product administration
Primary	The terminal elimination rate constant (?z) for paracetamol, guaifenesin and phenylephrine (total) in plasma	The terminal elimination rate constant is the rate at which the drug is removed from the body system	At baseline and during 12 hours after product administration
Primary	The mean residence time (MRT) for paracetamol, guaifenesin and phenylephrine (total)	Mean residence time (MRT) is the average amount of time that a single molecule of drug stays in the body	At baseline and during 12 hours after product administration
Secondary	Peak Plasma Concentration (Cmax) of unconjugated phenylephrine	The maximum observed plasma concentration (Cmax)	At baseline and during 12 hours after product administration
Secondary	The area under the plasma concentration-vs.-time curves from start of drug administration until the time of the last measurable concentration (AUCt) for unconjugated phenylephrine	AUCt is defined as area under the plasma concentration versus time curves from start of drug administration until the last measureable concentration.	At baseline and during 12 hours after product administration
Secondary	The area under the concentration-vs.-time curve extrapolated to infinity (AUC8) for unconjugated phenylephrine	AUC8 is defined as area under the plasma concentration versus time curves from start of drug administration until the plasma concentration is negligible (infinity).	At baseline and during 12 hours after product administration
Secondary	The extrapolated part of AUC8, AUCExtrap of unconjugated phenylephrine	AUCextrap is defined as area under the plasma concentration versus time curves from 12 hours until the plasma concentration is negligible (infinity).	From 12 hours after start of drug administration until up to 96 hours
Secondary	The time at which the maximum plasma concentration is observed (tmax) for unconjugated phenylephrine	Tmax is defined as the time point at which the maximum plasma concentration (Cmax) occurs	At baseline and during 12 hours after product administration
Secondary	The half-life (t1/2) for unconjugated phenylephrine in plasma	The half-life i defined as the time taken for the plasma concentration to fall to half its original value	At baseline and during 12 hours after product administration
Secondary	The terminal elimination rate constant (?z) for unconjugated phenylephrine in plasma	The terminal elimination rate constant is the rate at which the drug is removed from the body system	At baseline and during 12 hours after product administration
Secondary	The mean residence time (MRT) for unconjugated phenylephrine	Mean residence time (MRT) is the average amount of time that a single molecule of drug stays in the body	At baseline and during 12 hours after product administration

External Links

•   Redacted Study Synopsis